Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin

• Published in: Scientific reports Vol. 10; no. 1; p. 18481
• Main Authors: Szmit, Sebastian, Grela-Wojewoda, Aleksandra, Talerczyk, Małgorzata, Kufel-Grabowska, Joanna, Streb, Joanna, Smok-Kalwat, Jolanta, Iżycki, Dariusz, Chmielowska, Ewa, Wilk, Michał, Sosnowska-Pasiarska, Barbara
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28-10-2020; Nature Publishing Group
• Subjects: 692/4019; 692/4028; 692/499; Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Breast cancer; Breast Neoplasms - complications; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Cardiovascular diseases; Chemotherapy; Congestive heart failure; Doxorubicin; Doxorubicin - adverse effects; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; Endocrine therapy; Female; Heart failure; Heart Failure - chemically induced; Heart Failure - complications; Humanities and Social Sciences; Humans; Metastases; Metastasis; Middle Aged; Morbidity; Mortality; multidisciplinary; Multivariate analysis; Neoplasm Metastasis; Oncology; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Retrospective Studies; Risk Factors; Science; Science (multidisciplinary); Survival; Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-75614-4

Cardiovascular diseases (CVDs) are the major cause of morbidity/mortality among breast cancer (BC) patients. Observation of the daily practice in eight experienced Polish oncology centers was conducted to find all possible predictors of new cases of heart failure (HF) and overall survival (OS) of metastatic BC patients treated with liposomal doxorubicin, taking into account the impact of pre-existing CVDs. HF was the cause of premature discontinuation of liposomal doxorubicin therapy in 13 (3.2%) of 402 patients. The probability of developing HF was higher in women with pre-existing CVDs (HR 4.61; 95%CI 1.38–15.38). Independent of CVDs history, a lower risk of HF was observed in those treated with a cumulative dose of liposomal doxorubicin > 300 mg/m2 (HR 0.14; 95% CI 0.04–0.54) and taxane-naive (HR 0.26; 95% CI 0.07–0.96). Multivariate analysis including the presence of pre-existing CVDs and occurrence of new HF, revealed a liposomal doxorubicin in cumulative doses of > 300 mg/m2 as a beneficial predictor for OS (HR 0.61; 95% CI 0.47–0.78) independently of subsequent chemotherapy (HR 0.72; 95% CI 0.57–0.92) or endocrine therapy (HR 0.65; 95% CI 0.49–0.87). Higher doses of liposomal doxorubicin can decrease mortality in metastatic BC without increasing the risk of HF. The clinical benefit is achieved regardless of pre-existing CVDs and subsequent anticancer therapy.